



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – September 26, 2023

MEDDRAYSINTELL 10TH ANNIVERSARY EDITION OF NUCLEAR MEDICINE REPORT

MEDDraysintell releases the 10th Anniversary Edition of the Nuclear Medicine Report and Directory Edition 2023, comprising three volumes that provide a comprehensive and complete overview of the nuclear medicine landscape worldwide. They include a detailed analysis of existing marketed products, an evaluation of all radiopharmaceuticals in clinical or early-stage development, and a description of all associated companies. In addition, the report provides a comprehensive review of the radiopharmaceuticals market, encompassing key market players, recent trends and growth opportunities.

This new Edition-2023 provides a comprehensive and exhaustive review of the radiopharmaceutical sector, encompassing 1,070 products, including radionuclides, radiodiagnostic agents, and radiotherapeutics, along with in-depth profiles of 410 companies. This information is presented across three volumes (Marketed, Clinical and Early-Stage Radiopharmaceuticals), spanning more than 3,700 pages, and it includes as well over 3,600 direct web links to bibliographical references.

- MEDDraysintell Nuclear Medicine (Part 1) - Marketed Radiopharmaceuticals
- MEDDraysintell Nuclear Medicine (Part 2) - Clinical Radiopharmaceuticals
- MEDDraysintell Nuclear Medicine (Part 3) - Early-Stage Radiopharmaceuticals

Additionally, a database containing all the clinical and early-stage radiopharmaceuticals described in the reports can also be provided to assist users in their research.

**To request a detailed table of contents and sample pages, please contact
Paul-Emmanuel Goethals at peg@medraysintell.com**

Numerous possibilities are present within the radiopharmaceutical sector. These opportunities extend beyond diagnostic radiopharmaceuticals. The pipelines for radiotherapeutic development reveal a substantial number of products that could potentially hit the market by 2028.

There are multiple openings for larger corporations or investors to fund these developments and potentially collaborate with strategic partners through M&A.

About MEDDraysintell

MEDDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, cyclotron, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, with almost 4,900 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts.

We are proud to support numerous companies globally, helping them to better understand the markets, the competitive environment as well as the potential of merger and acquisitions (M&A) and technology development. We have repeated satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and university research laboratories.

MEDDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. The team brings together more than 50 years of expertise in the field of radiation healthcare. www.medraysintell.com

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00